

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number:

0 008 203**B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 25.08.82

(21) Application number: 79301564.5

(22) Date of filing: 03.08.79

(51) Int. Cl.³: **C 07 D 277/34,****C 07 D 407/12,****A 61 K 31/425,****A 61 K 31/44,****A 61 K 31/535 //C07C93/06**

(54) Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same.

(30) Priority: 04.08.78 JP 95673/78


(43) Date of publication of application:
20.02.80 Bulletin 80/4(45) Publication of the grant of the patent:
25.08.82 Bulletin 82/34(64) Designated Contracting States:
BE CH DE FR GB IT NL(56) References cited:
CHEMICAL ABSTRACTS, vol. 83, no. 83, 8th
December 1975, page 446, no. 193294u
Columbus, Ohio, U.S.A.(73) Proprietor: Takeda Chemical Industries, Ltd.
27, Doshomachi 2-chome
Higashi-ku Osaka, 541 (JP)(72) Inventor: Yutaka, Kauramatsu
15-3, Oharano-Kamisatoririmicho
Nishikyo-ku, Kyoto 610-11 (JP)
Inventor: Takesku, Fujita
13-15, Nagaodai 1-chome
Takarazuka, Hyogo 665 (JP)(74) Representative: Lewin, John Harvey et al,
Elkington and Fife High Holborn House 52/54
High Holborn
London WC1V 6SH (GB)**EP 0 008 203 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).


Courier Press, Leamington Spa, England.

Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same

This invention relates to novel thiazolidine derivatives having hypolipidemic and hypoglycemic activities with low toxicity. More particularly, the invention provides thiazolidine derivatives of the general formula (I) and salts thereof:



15 wherein R¹ is alkyl having 1 to 10 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, phenylalkyl having 7 to 11 carbon atoms, phenyl, a five- or six-membered heterocyclic group including one or two hetero-atoms selected from nitrogen, oxygen and sulphur, or a group of the formula




25 (where R³ and R⁴ are the same or different and each means alkyl having 1 to 4 carbon atoms), the cycloalkyl, phenylalkyl, phenyl and heterocyclic groups optionally having 1 to 3 substituents on the respective rings, or optionally having an alkylenedioxy group of the formula —O—(CH₂)_m—O— [*m* is an integer of 1 to 3] attached to two adjacent carbon atoms on the ring to form an additional ring; R² is a bond or an alkylene group having 1 to 3 carbon atoms; L¹ and L² may be the same or different and

30 each is alkyl having 1 to 3 carbon atoms or L¹ or L² are combined with each other to form an alkylene group having 2 to 6 carbon atoms, provided that when R¹ is other than alkyl, L¹ and L² may further be hydrogen.

Referring to the general formula (I), the alkyl group R¹ may be a straight-chain or branched alkyl of 1 to 10 carbon atoms, such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl, *n*-pentyl, *i*-


35 pentyl, *n*-hexyl, *n*-heptyl, *n*-octyl, *n*-nonyl, and *n*-decyl; the cycloalkyl group R¹ is a cycloalkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl; and the phenylalkyl group R¹ is a phenylalkyl group of 7 to 11 carbon atoms such as benzyl and phenethyl. Examples of the heterocyclic group R¹ include 5- or 6-membered groups each including 1 or 2 hetero-atoms selected from nitrogen, oxygen and sulphur, such as pyridyl, thienyl, furyl, thiazolyl, piperidino morpholino,

40 pyrrolidino and piperazino. When R¹ is



the alkyls R³ and R⁴ are each an alkyl of 1 to 4 carbon atoms such as methyl, ethyl, *n*-propyl, *i*-propyl and *n*-butyl.


The alkylene group R² contains 1 to 3 carbon atoms and, thus, may for example be methylene, ethylene or trimethylene. The bond R² is equivalent to the symbol "—", "—" or the like which is used in chemical structural formulae, and when R² represents such a bond, the compound of general formula (I) is represented by the following general formula (II):



Examples of the alkyls L¹ and L² having 1 to 3 carbon atoms include methyl and ethyl. The alkylene group formed when L¹ and L² are joined together is a group of the formula —(CH₂)_n—[where *n* is an integer of 2 to 6].

The cycloalkyl, phenylalkyl, phenyl and heterocyclic groups mentioned above may have 1 to 3 substituents in optional positions on the respective rings. Examples of such substituents include lower alkyls (e.g. methyl or ethyl), lower alkoxy groups (e.g. methoxy or ethoxy), halogens (e.g. chlorine or bromine) and hydroxyl. Also within the scope of the general formula (I) is an alkylenedioxy group of the formula $\text{—O—(CH}_2\text{)}_m\text{—O—}$ [m is an integer of 1 to 3], such as methylenedioxy, which is attached to two adjacent carbon atoms on the ring to form an additional ring.

The compound (I) according to this invention can be converted to various salts by procedures known *per se*. For example, when the heterocyclic group R¹ includes a tertiary nitrogen atom, or R¹ means a group for the formula




20 the compound (I) can be converted to acid salts with acids, such as hydrochloric acid, sulphuric acid, acetic acid or oxalic acid. When R¹ does not include a tertiary nitrogen atom, the compound may be converted to salts with cations such as sodium ion, potassium ion, calcium ion or ammonium ion.


The thiazolidine derivative (I) according to this invention has activity to lower the blood sugar and triglyceride levels in mice (KKAY) with spontaneous diabetes and is expected to be of value in the treatment of hyperlipemia, diabetes and their complications in mammals including human beings. The compound (I) has low toxicity. For example, the LD₅₀ value of 5-[4-(1-methyl-cyclohexylmethoxy)benzyl] thiazolidine-2,4-dione in the rat is more than 10 g/kg. (P.O.). The compound (I) may be orally administered in dosage forms such as tablets, capsules, powders or granules, or by other routes in such forms as injections, suppositories, pellets and so on. The compound (I) may be mixed with a non-toxic, pharmaceutically acceptable carrier or diluent. Taking the treatment of hyperlipemia as an example, the compound may be orally or otherwise administered at a normal daily dose level of 50 mg to 1 gram per adult human. For treatment of diabetes, the compound (I) may be orally or otherwise administered at a normal daily dose of 10 mg to 1 gram per adult human.

The thiazolidine derivative (I) of this invention may be produced, for example, by the following methods.

(1) The thiazolidine derivative (II) can be produced by the steps of reacting a compound of the general formula (III) with thiourea to obtain an 2-iminothiazolidine derivative of the general formula (IV) and, then, hydrolyzing the last-mentioned derivative (IV).




wherein R¹, R², L¹ and L² have the meanings respectively defined hereinbefore; X¹ means halogen (e.g. chlorine or bromine), alkylsulphonyloxy (e.g. methylsulphonyloxy) or arylsulphonyloxy (e.g. toluenesulphonyloxy); Z is alkoxy having 1 or 2 carbon atoms (i.e. methoxy or ethoxy), hydroxyl, amino or a group of the formula —OM (M is an alkali metal atom, e.g. Na or K, or NH₄).



wherein R¹, R², L¹ and L² have the meanings respectively defined hereinbefore.


The compound (IV) may tautomerically take the form as below:



[wherein R¹, R², L¹ and L² have the meanings respectively defined hereinbefore]. In this specification, the nomenclature and formula of these compounds are described *en bloc* as "2-iminothiazolidine derivative" and as formula (IV), respectively.

The reaction between a compound (III) and thiourea is normally conducted in a solvent. Examples of such solvents include alcohols (e.g. methanol, ethanol, propanol, butanol or ethylene glycol monomethyl ether), ethers (e.g. tetrahydrofuran or dioxane), acetone, dimethylsulphoxide, sulpholane, and dimethylformamide. While the relative amounts of starting materials need not be critically controlled, it is normally desirable to employ a slight excess of thiourea based on compound (III). Thus, 1 to 2 molecular equivalents of thiourea are preferably employed relative to compound (III). While the conditions of reaction such as reaction temperature and time depend on such factors as the starting material, solvent, etc., this reaction is normally carried out at the boiling point of the solvent used or at 100 to 130°C for a few to ten and odd hours. The sparingly soluble imino-compound (IV) is produced in the above manner. This imino-compound (IV) may be isolated prior to the following hydrolysis step or the reaction mixture containing (IV) may be directly hydrolyzed. In the hydrolysis step, the imino-compound (IV) is heated in a suitable solvent (e.g. sulpholane) and in the presence of water and mineral acid. The acid just mentioned is added normally in a proportion of 0.1 to 10 molecular equivalents, preferably 0.2 to 3 equivalents, based on compound (III), while water is used normally in a large excess based on compound (III). The heating time normally ranges from a few hours to 10 and odd hours.


(2) The thiazolidine derivative (I) can further be produced by subjecting a compound of the formula (V):



40 wherein L¹, L², R¹ and R² have the meanings given above, and R⁵ means alkyl having 1 to 4 carbon atoms (e.g. methyl, ethyl, *n*-propyl, *n*-butyl or *t*-butyl), aryl having 6 to 8 carbon atoms (e.g. tolyl) or aralkyl having 7 or 8 carbon atoms (e.g. benzyl) to a cyclization reaction. This cyclization reaction is usually carried out by hydrolyzing a compound (V) with water. The hydrolysis is generally conducted in the presence of a catalyst, examples which include hydrogen halides (e.g. hydrogen chloride or hydrogen bromide), or mineral acids such as hydrochloric acid or sulphuric acid. The catalyst may generally be used in amount of from 20 to 50 mol equivalent relative to the compound (V). This reaction may be conducted in the presence of an organic solvent such as an alcohol (e.g. methanol or ethanol). While the reaction temperature varies with the type of catalyst used, the reaction may generally be carried out at a temperature ranging from 50 to 150°C. The reaction time is usually in the range of from 2 to 30

50 hours.

(3) The thiazolidine derivative (I) can also be produced by reacting a compound of the formula (VI):



60 with a compound of the formula (VII):



wherein L¹, L², R¹ and R² have the meanings given above, and X² means a halogen atom such as chlorine or bromine, in the presence of a base. Examples of the base, include sodium hydride, potassium carbonate, sodium carbonate, potassium hydroxide and sodium hydroxide. This reaction is usually carried out in the presence of a solvent. Suitable solvents include dimethylformamide and dimethylsulphoxide. The reaction temperature may be in the range of from room temperature to 100°C.

The resulting thiazolidine derivative (I) can be isolated and purified by conventional procedures such as concentration at atmospheric or subatmospheric pressure, solvent extraction, crystallization, recrystallization, phasic transfer or chromatography.

The compound (III) which is used as the starting material in the above preparation method (1) can be produced, for example, by the steps of diazotizing the corresponding aniline compound and subjecting the diazo-compound to Meerwein arylation.

The following reference and working Examples are given to illustrate this invention in further detail.

Reference Example 1

19.0 g of 4-[2-(N,N-dibutylamino)ethyloxy]nitrobenzene are dissolved in 200 ml of methanol and, after 3 g of 10% Pd-C (50% wet) are added, catalytic reduction is carried out at atmospheric temperature and pressure. The reaction system absorbs about 4.4 l of hydrogen in 75 minutes. The catalyst is then filtered off, the filtrate is concentrated under reduced pressure and the oily residue is dissolved in a mixture of 100 ml methanol and 100 ml acetone. Following the addition of 21.5 ml of concentrated hydrochloric acid, the solution is cooled to 0°C and a solution of 4.9 g sodium nitrite in 10 ml water is added dropwise at a temperature not exceeding 5°C. The mixture is stirred at 5°C for 20 minutes, at the end of which time 33.3 g (34.9 ml) of methyl acrylate are added. The reaction mixture is heated to 35°C and 1 g of cuprous oxide is added in small portions, whereupon the temperature of the reaction system rises to 44°C with the evolution of nitrogen gas. The mixture is stirred for one hour and after the temperature has dropped to room temperature, it is allowed to stand overnight. The solvent is then distilled off under reduced pressure and the residue is made strongly basic with concentrated aqueous ammonia. Then, following the addition of water, extraction is carried out with ethyl acetate. The extract is washed with water, dried over sodium sulphate and distilled to remove the ethyl acetate. The oily residue is chromatographed on a column of 200 g silica gel, elution being carried out with ether-*n*-hexane (1:4). The above procedure yields 10.7 g (44.8%) of methyl 2-chloro-3-[4-[2-(N,N-dibutylamino)ethyloxy]phenyl]propionate.

IR (liquid film) $\nu_{\max}^{\text{cm}^{-1}}$: 2945, 2850, 1745, 1605, 1505, 1250, 1170, 1030
NMR δ ppm CDCl₃: 0.93(6H,t), 1.2—1.8(8H,m), 2.52(4H,t), 2.83(2H,t), 3.0—3.5(2H,m), 3.7(3H,s), 4.0(2H,t), 4.4(1H,t), 6.75—7.30(4H,q)

Example 1

a) A mixture of 3.6 g of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate, 0.73 g of thiourea and 3 ml of sulpholane is heated at 120°C for 4 hours and, after cooling, 15 ml of water are added. The oil is separated, ether is added to the oil and the crystalline insolubles (a) are separated from the solution (b) by filtration. The filtrate (b) is distilled to remove the solvent and the residue is run onto a column of 100 g of silica gel, elution being carried out with chloroform. The above procedure yields 1.7 g of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidine-2,4-dione. m.p. 107—108°C (benzene-ligroin)

On the other hand, the crystals (a) are recrystallized from ethanol-acetone (3:1) to obtain 1 g of 2-imino-5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidin-4-one with a decomposition point of 210—212°C. A 300 mg portion of this crystalline product is boiled with 2 ml of sulpholane and 2 ml of 6N-HCl at 110°C for 5 hours. After cooling, 50 ml of water are added and the resulting crystals are recrystallized from benzene-ligroin. The above procedure yields 250 mg of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidine-2,4-dione.

Example 2

A mixture of 27 g of ethyl 2-chloro-3-[4-(2-phenylpropyloxy)phenyl]propionate, 11 g of thiourea and 60 ml of sulpholane is heated at 110°C for 6 hours and, then, boiled with 10 ml of 2N-sulphuric acid (or 2 ml of 6N-HCl) for 16 hours. After cooling, 1 l of water is added and the oil is separated and allowed to stand for a while, whereupon crystals separate out. These crystals are recrystallized from benzene-ligroin. The above procedure yields 19.9 g of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidine-2,4-dione.

Example 3

a) 333 mg of 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionic acid and 150 mg of thiourea are heated with 2 ml of sulpholane at 120°C for 1.5 hours and, following the addition of 2 ml of 6N-HCl, the mixture is further heated for 5 hours, at the end of which time 10 ml of water are

added. The resulting crystals are recovered by filtration. The above procedure yields 310 mg of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidine-2,4-dione.

b) The same procedure as that described in a) is repeated except that 355 mg of sodium 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate are employed. This procedure yields 310 mg of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidine-2,4-dione.

c) The same procedure as that described in a) is repeated except that 332 mg of 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionamide are employed. This procedure yields 340 mg of 5-[4-(2-methyl-2-phenylpropyloxy)-benzyl]thiazolidine-2,4-dione.

d) 1.8 g of ammonium 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate and 0.8 g of thiourea are dissolved in 10 ml of ethanol and the solution is heated for 5 hours, at the end of which time 50 ml of water are added.

The above procedure yields 1.6 g of 2-imino-5-[4-(2-methyl-2-phenylpropyloxy)benzyl]-thiazolidin-4-one.

Example 4

200 mg of 2-bromo-3-[4-(4-chlorobenzoyloxy)phenyl]propionic acid and 100 mg of thiourea are dissolved in 2 ml of dimethylsulphoxide and the solution is heated at 110°C for 3 hours. Then, after 0.5 ml of water is added, the solution is further heated for 5 hours. Then, 10 ml of water are added and the resulting crystals are recovered by filtration and recrystallized from benzene-*n*-hexane (1:1). The above procedure yields 170 mg of 5-[4-(4-chlorobenzoyloxy)benzyl]thiazolidine-2,4-dione.

Example 5

1.9 g of ethyl 3-[4-(2-methyl-2-phenylpropyloxy)phenyl]-2-thiocyanatopropionate is dissolved in 20 ml of ethanol and 20 ml of 6N-hydrochloric acid are added to the solution. The mixture is refluxed for 24 hours. After cooling, water is added to the mixture. The mixture is subjected to extraction with ether. The extract is washed with water and then dried. After distilling off ether, the residue is crystallized from ether-*n*-hexane, whereby 730 mg of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]-thiazolidine-2,4-dione are obtained.

Example 6

2.1 g of ethyl 2-methanesulphonyloxy-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate and 0.76 g of thiourea are added to 20 ml of sulfolane, and the mixture is heated at 120°C with stirring for one hour. After adding 10 ml of 2N-hydrochloric acid, the mixture is heated at 100°C for 8 hours. After cooling, water is added to the mixture, and the mixture is subjected to extraction with ether. The extract is washed with water and dried. The ether is distilled off to give 1.3 g of 5-[4-(2-methyl-2-phenylpropyloxy)benzyl]thiazolidine-2,4-dione.

Example 7

2.0 g of ethyl 2-methanesulphonyloxy-3-[4-(1-methylcyclohexylmethyloxy)phenyl]propionate and 760 mg of thiourea are added to 20 ml of ethanol. The mixture is refluxed for 2 hours. 10 ml of hydrochloric acid, are added to the mixture and the mixture is further refluxed for 16 hours. After cooling, water is added to the mixture. The mixture is subjected to extraction with ethyl acetate. The extract is washed with water and dried. The ethyl acetate is distilled off to give 1.4 g of 5-[4-(1-methylcyclohexylmethyloxy)benzyl]thiazolidine-2,4-dione. Crystallization from 85% ethanol give crystals melting at 130 to 131°C.

Example 8

1.12 g of 5-(4-hydroxybenzyl)thiazolidine-2,4-dione, is dissolved in 12 ml of dimethylsulphoxide and 480 mg of 50% sodium hydride in oil are added to the solution.


The mixture is stirred at room temperature for 15 minutes, followed by addition of 0.81 g of 4-chlorobenzyl chloride. The whole mixture is stirred at 50°C for 4 hours. Water is added to the mixture and the mixture is acidified with 2N-hydrochloric acid. The mixture is subjected to extraction with ether. The extract is washed with water and dried. Ether is distilled off to give an oily substance. The oily substance is subjected to column chromatography on 30 g silica gel, elution being carried out with cyclohexane-ethyl acetate (2:1). The above procedure yields 425 mg of 5-[4-(4-chlorobenzoyloxy)-benzyl]thiazolidine-2,4-dione.

0 008 203

Example 9

By procedures analogous to those described above in Examples 1 to 4, the following compounds were synthesized.

5



10

15

20

25

30

35

40









45







50

55










60











65










Compound No.	A	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
1		benzene-n-hexane	85-86	1,4
2		benzene-cyclohexane	135-136	1
3		benzene-ligroin	156-158	1,3
4		Isopropyl ether	128-129	1
5		Ether-n-hexane	103-104	1,2
6		Cyclohexane	102-103	1
7		Cyclohexane	101-102	2
8		Cyclohexane	101-102	2

Compound No.	A	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
9	$\begin{array}{c} \text{CH}_3 \\ \\ \text{n-C}_7\text{H}_{15}-\text{C}-\text{CH}_2- \\ \\ \text{CH}_3 \end{array}$	Cyclohexane	101-102	2
10	$\begin{array}{c} \text{CH}_3 \\ \\ \text{CH}_3-\text{C}-\text{CH}_2\text{CH}_2- \\ \\ \text{CH}_3 \end{array}$	Ether-n-hexane	101-102	1,2
11	$\begin{array}{c} \text{C}_2\text{H}_5 \\ \\ \text{n-C}_3\text{H}_7-\text{C}-\text{CH}_2- \\ \\ \text{C}_2\text{H}_5 \end{array}$	n-Hexane	69-70	2
12		Benzene-Ilgroin	93-94	1,3
13		Ethyl acetate-cyclohexane	79.80	1
14		Ethyl acetate-cyclohexane	82-83	1
15		Ethyl acetate-n-hexane	130-131	2
16		Ether-n-hexane	87-88	2
17		Ethyl acetate	148-149	2

Compound No.	A	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
18		Ethyl acetate-n-hexane	104-105	2
19		Ether-n-hexane	72-73	2
20		Ethyl acetate-n-hexane	102-103	2
21		Ether-n-hexane	110-111	2
22			Oil IR (cm ⁻¹) 3200, 1750, 1700, 1240 liquid film	2
23		Ethyl acetate-n-hexane	92-93	2
24		Ethyl acetate-n-hexane	108.5-109.5	2
25		Ethyl acetate-ether	132-133	2
26		Ether-n-hexane	84-85	1

Compound No.	A	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
27		Ether-n-hexane	66-67	1,3
28		Ether-n-hexane	107-108	1
29		Cyclohexane	106-107	2
30		Ether-n-hexane	104-105	2
31		Ether-n-hexane	107-108	2
32		Ether-n-hexane	68-69	2
33		Ether-n-hexane	116-117	2
34		Ether-n-hexane	87-88	2
35		Ether	157-158	2

Compound No.	A	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
36		Ether-n-hexane	106-107	2
37		Methanol	183-184	1
38		Chloroform-methanol	175-176	1,2
39		Chloroform-methanol	176-177	2
40		DMF-H ₂ O	209-210	1,2
41		Methanol	167-168	2
42		Ethyl acetate-n-hexane.	103-104	2
43		Ether-n-hexane	73-74	2
44		Ether-n-hexane	62-64	2
45		Ethanol	193-194.5	1

Compound No.	A	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
46		Cyclohexane	82–83	1
47		n-Propanol	121–122	1,2
48		Benzene-ligroin	137–138	1,2
49		Cyclohexane	124–125	1,5
50		Ligroin	88–89	1
51		n-Hexane	68–69	1
52		Benzene-ligroin	136–137	1
53		Ether-n-hexane	88–89	2
54		Ether-n-hexane	110–111	2

Example 10

A mixture of 10.0 g of methyl 2-chloro-3-[4-(2-morpholinoethoxy)phenyl]propionate and 4.64 g thiourea is heated in the presence of 100 ml of sulpholane at 120°C for 4 hours. After cooling, a saturated aqueous solution of sodium hydrogen carbonate is added and the mixture is extracted with ethyl acetate. The extract is washed with water, dried over sodium sulphate and distilled to remove the ethyl acetate, whereupon 4.1 g (40.2%) of 2-imino-5-[4-(2-morpholinoethoxy)benzyl]thiazolidin-4-one are obtained as crystals. These crystals are recrystallized from ethyl acetate-methanol. Colourless needles, m.p. 189—190°C.

4.1 g of the above 2-imino-5-[4-(2-morpholinoethoxy)benzyl]thiazolidin-4-one are dissolved in 50 ml of 2N—HCl and the solution is heated under reflux for 16 hours. After cooling, the reaction mixture is neutralised with a saturated aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The extract is washed with water, dried over sodium sulphate and distilled to remove the ethyl acetate, whereupon 3.8 g (92.7%) of 5-[4-(2-morpholinoethoxy)benzyl]thiazolidine-2,4-dione are obtained as crystals. These crystals are recrystallized from dimethylformamide-water. Colourless prisms, m.p. 188—189°C.


Example 11

A mixture of 9.0 g methyl 2-chloro-3-[4-[2-(N,N-diisopropylamino)ethoxy]phenyl]propionate and 2.4 g thiourea is heated in the presence of 100 ml of *n*-butanol at 100°C for 15 hours. After cooling, the *n*-butanol is distilled off under reduced pressure, 100 ml of 2N—HCl are added to the residue and the mixture is heated at 100°C for 6 hours. After cooling, the reaction mixture is neutralized with a saturated aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The extract is washed with water, dried (over Na₂SO₄) and distilled to remove the ethyl acetate, whereupon 6.0 g (65.2%) of 5-[4-[2-(N,N-diisopropylamino)ethoxy]benzyl]thiazolidine-2,4-dione are obtained as crystals. These crystals are recrystallized from ethanol. Colourless prisms, m.p. 134—135°C.

Example 12

By procedures analogous to those described in Examples 10 or 11, the following compounds were synthesized.

0008 203



Compound No.	B	Recrystallization solvent	m.p. (°C)	Analogous Example No(s).
1	$\begin{array}{c} \text{CH}_3 \\ \diagup \\ \text{N}- \\ \diagdown \\ \text{CH}_3 \end{array} \cdot \text{HCl}$	Ethanol	208–209	10; 11
2	$\begin{array}{c} \text{C}_2\text{H}_5 \\ \diagup \\ \text{N}- \\ \diagdown \\ \text{C}_2\text{H}_5 \end{array} \cdot \text{HCl}$	Ethanol	146–147	10; 11
3	$\begin{array}{c} n\text{-C}_3\text{H}_7 \\ \diagup \\ \text{N}- \\ \diagdown \\ n\text{-C}_3\text{H}_7 \end{array}$	Ethanol	124–125	11
4	$\begin{array}{c} i\text{-C}_3\text{H}_7 \\ \diagup \\ \text{N}- \\ \diagdown \\ i\text{-C}_3\text{H}_7 \end{array}$	Ethanol	134–135	11
5	$\begin{array}{c} n\text{-C}_4\text{H}_9 \\ \diagup \\ \text{N}- \\ \diagdown \\ n\text{-C}_4\text{H}_9 \end{array}$	Ethanol	98–99	10, 11
6	$\begin{array}{c} \text{C}_6\text{H}_{11} \\ \diagup \\ \text{N}- \\ \diagdown \end{array} \cdot \text{HCl}$	Methanol	232–234	11
7	$\begin{array}{c} \text{C}_6\text{H}_{11} \\ \diagup \\ \text{N}- \\ \diagdown \end{array} \cdot \text{HCl}$	methanol	244–245	11

Example 13

An example of a practical recipe in which the compound of this invention is utilized as a remedy for diabetes is as follows:


(Tablet)

(1)	5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione	10 mg
(2)	lactose	35 mg
(3)	corn starch	170 mg
(4)	microcrystalline cellulose	30 mg
(5)	magnesium stearate	5 mg
		<u>250 mg</u>


(1), (2), (3) and 2/3 quantity of (4) are thoroughly mixed, and then the mixture is granulated. The remaining 1/3 quantity of (4), and (5) are added to the granules and the product is compressed into tablets. The tablets thus prepared can further be coated with a suitable coating agent.

Claims

1. A thiazolidine derivative of the general formula (I):



wherein R¹ is alkyl having 1 to 10 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, phenylalkyl having 7 to 11 carbon atoms, phenyl, a five- or six-membered heterocyclic group including one or two hetero-atoms selected from nitrogen, oxygen and sulphur, or a group of the formula



(wherein R³ and R⁴ are the same or different and each is alkyl having 1 to 4 carbon atoms), the cycloalkyl, phenylalkyl, phenyl and heterocyclic groups optionally having 1 to 3 substituents on the respective rings, or optionally having an alkylendioxy group of the formula —O—(CH₂)_m—O— [m is an integer of 1 to 3] attached to two adjacent carbon atoms on the ring to form an additional ring; R² means a bond or an alkylene group having 1 to 3 carbon atoms; L¹ and L² are the same or different and each is alkyl having 1 to 3 carbon atoms or L¹ and L² are combined to form an alkylene group having 2 to 6 carbon atoms, provided that, when R¹ is other than alkyl, L¹ and L² may further be hydrogen, or a salt thereof.

2. A thiazolidine derivative as claimed in claim 1, wherein R¹ is an alkyl having 1 to 10 carbon atoms.

3. A thiazolidine derivative as claimed in claim 1, wherein L¹ and L² are combined to form an alkylene group having 2 to 6 carbon atoms.

4. A thiazolidine derivative as claimed in claim 1, wherein R² is a lower alkylene group having 1 to 3 carbon atoms.


5. A thiazolidine derivative as claimed in claim 1, wherein R¹ is an alkyl having 1 to 10 carbon atoms; L¹ and L² are combined to form an alkylene group having 2 to 6 carbon atoms; and R² is an alkylene group having 1 to 3 carbon atoms.

6. A thiazolidine derivative as claimed in claim 1, which is 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione.


7. A pharmaceutical composition, which comprises as an active ingredient, an effective amount of a thiazolidine derivative as defined in Claim 1.

8. A pharmaceutical composition as claimed in claim 1, wherein the derivative is 5-[4-(1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione.

9. A process for the production of a thiazolidine derivative of the general formula (I) as defined in Claim 1, which process comprises reacting a compound of the formula (III):




wherein R¹, R², L¹ and L² have the meanings respectively defined in Claim 1; X¹ means halogen, alkylsulphonyloxy or arylsulphonyloxy; and Z is alkoxy having 1 or 2 carbon atoms, hydroxyl, amino or a group of the formula —OM (wherein M is an alkali metal atom or NH₄), with thiourea to obtain an 2-iminothiazolidine derivative of the formula (IV):




wherein R¹, R², L¹ and L² have the meanings respectively defined in claim 1, and, then, hydrolyzing the last-mentioned 2-iminothiazolidine derivative.

Revendications

1. Dérivé de thiazolidine de formule générale (I)



où R¹ est un alcoyle ayant de 1 à 10 atomes de carbone, un cycloalcoyle ayant de 3 à 7 atomes de carbone, un phénylcoyle ayant de 7 à 11 atomes de carbone, un phényle, un groupe hétérocyclique à cinq ou six chaînons comprenant un ou deux hétéro-atomes choisis entre l'azote, l'oxygène et le soufre, ou un groupe de formule



(où R³ et R⁴ sont semblables ou différents et représentent chacun un alcoyle ayant de 1 à 4 atomes de carbone), les groupes cycloalcoyle, phényl alcoyle, phényle et hétérocycliques ayant éventuellement de 1 à 3 substituants sur les noyaux respectifs, ou éventuellement ayant un groupe alcoylènedioxy de formule —O—(CH₂)_m—O— [*m* est un nombre entier allant de 1 à 3] attaché à deux atomes de carbone adjacents sur le noyau pour former un noyau supplémentaire; R² désigne une liaison ou un groupe alcoylène ayant de 1 à 3 atomes de carbone; L¹ et L² sont semblables ou différents et chacun est un alcoyle ayant de 1 à 3 atomes de carbone ou L¹ et L² sont combinés pour former un groupe alcoylène ayant de 2 à 6 atomes de carbone, à condition que, lorsque R¹ est différent d'un alcoyle, L¹ et L² puissent en outre être un hydrogène, ou un de ses sels.

2. Dérivé de thiazolidine tel que revendiqué dans la revendication 1, où R¹ est un alcoyle ayant de 1 à 10 atomes de carbone.

3. Dérivé de thiazolidine tel que revendiqué dans la revendication 1, où L¹ et L² sont combinés pour former un groupe alcoylène ayant de 2 à 6 atomes de carbone.

4. Dérivé de thiazolidine tel que revendiqué dans la revendication 1, où R² est un groupe alcoylène inférieur ayant de 1 à 3 atomes de carbone.


5 5. Dérivé de thiazolidine tel que revendiqué dans la revendication 1, où R¹ est un alcoyle ayant de 1 à 10 atomes de carbone; L¹ et L² sont combinés pour former un groupe alcoylène ayant de 2 à 6 atomes de carbone; et R² est un groupe alcoylène ayant de 1 à 3 atomes de carbone.

6. Dérivé de thiazolidine tel que revendiqué dans la revendication 1, qui est la 5-[4-(1-méthylcyclohexylméthoxy)benzyl]thiazolidine-2,4-dione.


10 7. Composition pharmaceutique contenant comme ingrédient actif une quantité efficace d'un dérivé de thiazolidine tel que défini dans la revendication 1.

8. Composition pharmaceutique telle que revendiquée dans la revendication 1, où le dérivé est la 5-[4-(1-méthylcyclohexylméthoxy)benzyl]thiazolidine-2,4-dione.

9. Procédé de préparation d'un dérivé de thiazolidine de formule générale (I) telle que définie dans la revendication 1, dans lequel on fait réagir un composé de formule (III):




où R¹, R², L¹ et L² ont les significations respectivement définies dans la revendication 1; X¹ représente un halogène, un alcoylsulfonyloxy ou un arylsulfonyloxy; et Z est un alcoxy ayant 1 ou 2 atomes de carbone, un hydroxyle, un amino ou un groupe de formule —OM (où M est un atome de métal alcalin ou NH₄), avec de la thiourée pour obtenir un dérivé de 2-iminothiazolidine de formule (IV):



où R^1 , R^2 , L^1 et L^2 ont les significations respectivement définies dans la revendication 1, puis on hydrolyse le dérivé de 2-iminothiazolidine mentionné en dernier.


Patentansprüche

1. Thiazolidin-Derivat der allgemeinen Formel (I)



55 in der

R¹ für Alkyl mit 1 bis 10 Kohlenstoff-Atomen, Cycloalkyl mit 3 bis 7 Kohlenstoff-Atomen, Phenylalkyl mit 7 bis 11 Kohlenstoff-Atomen, Phenyl, eine fünf- oder sechsgliedrige heterocyclische Gruppe mit einem oder zwei Heteroatomen ausgewählt aus Stickstoff, Sauerstoff und Schwefel oder eine Gruppe der Formel



(in der R³ und R⁴ gleich oder verschieden sind und jeweils ein Alkyl mit 1 bis 4 Kohlenstoff-Atomen bezeichnen) steht, wobei die Cycloalkyl-, Phenylalkyl-, Phenyl- und heterocyclischen Gruppen an den betreffenden Ringen gegebenenfalls 1 bis 3 Substituenten tragen oder gegebenenfalls eine an zwei benachbarte Kohlenstoff-Atome des Ringes gebundene Alkylendioxy-Gruppe der Formel $\text{—O—(CH}_2\text{)}_m\text{—O—}$ (wobei m eine ganze Zahl von 1 bis 3 bezeichnet), die einen zusätzlichen Ring bildet, enthalten.

R² für eine Bindung oder eine Alkylen-Gruppe mit 1 bis 3 Kohlenstoff-Atomen steht, und

10 L¹ und L² gleich oder verschieden sind und jeweils für ein Alkyl mit 1 bis 3 Kohlenstoff-Atomen stehen, oder L¹ und L² zusammen genommen eine Alkyl-Gruppe mit 2 bis 6 Kohlenstoff-Atomen bilden, mit der Maßgabe, daß, wenn R¹ kein Alkyl ist, L¹ und L² weiterhin auch Wasserstoff sein können, oder eines seiner Salze.

2. Thiazolidin-Derivat nach Anspruch 1, dadurch gekennzeichnet, daß R^1 ein Alkyl mit 1 bis 10 Kohlenstoff-Atomen ist.

3. Thiazolidin-Derivat nach Anspruch 1, dadurch gekennzeichnet, daß L¹ und L² zusammen ge-
nommen eine Alkyl-Gruppe mit 2 bis 6 Kohlenstoff-Atomen bilden.

4. Thiazolidin-Derivat nach Anspruch 1, dadurch gekennzeichnet, daß R^2 eine niedrigere Alkylengruppe mit 1 bis 3 Kohlenstoff-Atomen ist.


5. Thiazolidin-Derivat nach Anspruch 1, dadurch gekennzeichnet, daß R¹ ein Alkyl mit 1 bis 10 Kohlenstoff-Atomen ist, L¹ und L² zusammen genommen eine Alkylengruppe mit 2 bis 6 Kohlenstoff-Atomen bilden und R² eine Alkylengruppe mit 1 bis 3 Kohlenstoff-Atomen ist.

6. Thiazolidin-Derivat 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidin-2,4-dion nach Anspruch 1.

7. Pharmazeutische Zusammensetzung, enthaltend als Wirkstoff eine wirksame Menge eines Thiazolidin-Derivates wie in Anspruch 1 definiert.

25 8. Pharmazeutische Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß das Derivat 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidin-2,4-dion ist.

9. Verfahren zur Herstellung eines Thiazolidin-Derivats der allgemeinen Formel (I) wie in Anspruch 1 definiert, dadurch gekennzeichnet, daß eine Verbindung der Formel (III)




35 in der R^1 , R^2 , L^1 und L^2 jeweils die in Anspruch 1 angegebenen Bedeutungen haben,

X¹ Halogen, Alkylsulfonyloxy oder Arylsulfonyloxy bezeichnet und

Z für Alkoxy mit 1 oder 2 Kohlenstoff-Atomen, Amino oder eine Gruppe der Formel —OM (worin M ein Alkali-metall-Atom oder NH_4 ist) steht,

40 mit Thioharnstoff unter Bildung eines 2-Iminothiazolidin-Derivats der Formel (IV)



in der R¹, R², L¹ und L² jeweils die in Anspruch 1 angegebenen Bedeutungen haben, umgesetzt wird und dann das zuletzt genannte 2-Imino-thiazolidin-Derivat hydrolysiert wird.